Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
49
BAYZF Quote, Financials, Valuation and Earnings
Last price:
$51.06
Seasonality move
:
1.56%
Day range:
$53.88 - $53.88
52-week range:
$20.99 - $58.33
Dividend yield:
0.23%
P/E ratio:
--
P/S ratio:
1.05x
P/B ratio:
1.52x
Volume:
561
Avg. volume:
10.3K
1-year change:
142.4%
Market cap:
$52.9B
Revenue:
$50.4B
EPS (TTM):
-$0.35
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
BAYZF
Bayer AG
|
$13.3B | -- | 11.17% | -- | -- |
|
BNTX
BioNTech SE
|
$963.1M | -$0.10 | 93.93% | -31.18% | $139.76 |
|
IFRX
InflaRx NV
|
$30.9K | -$0.17 | -74.55% | -70.4% | $10.46 |
|
IMTX
Immatics NV
|
$10.9M | -$0.47 | -81.87% | -704.25% | $19.13 |
|
MDGEF
Medigene AG
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
BAYZF
Bayer AG
|
$53.88 | -- | $52.9B | -- | $0.13 | 0.23% | 1.05x |
|
BNTX
BioNTech SE
|
$110.42 | $139.76 | $27.7B | 191.55x | $0.00 | 0% | 7.51x |
|
IFRX
InflaRx NV
|
$0.87 | $10.46 | $59.1M | -- | $0.00 | 0% | 269.55x |
|
IMTX
Immatics NV
|
$10.30 | $19.13 | $1.3B | 42.21x | $0.00 | 0% | 13.76x |
|
MDGEF
Medigene AG
|
-- | -- | -- | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
BAYZF
Bayer AG
|
57.27% | -0.125 | 142.49% | 0.55x |
|
BNTX
BioNTech SE
|
1.31% | 1.308 | 1.22% | 6.78x |
|
IFRX
InflaRx NV
|
2.1% | -0.262 | 1.26% | 2.34x |
|
IMTX
Immatics NV
|
3.78% | 2.067 | 1.86% | 6.97x |
|
MDGEF
Medigene AG
|
-- | 0.000 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
BAYZF
Bayer AG
|
$6.3B | $655.6M | -0.4% | -0.91% | 5.81% | $648.4M |
|
BNTX
BioNTech SE
|
$1.6B | $743.4M | -2.96% | -3.01% | 41.89% | $785.5M |
|
IFRX
InflaRx NV
|
-$89.2K | -$11.7M | -80.95% | -82.01% | -42057.91% | -$11.4M |
|
IMTX
Immatics NV
|
-- | -$63.9M | -24.18% | -25.21% | -1053.82% | -$56.2M |
|
MDGEF
Medigene AG
|
-- | -- | -- | -- | -- | -- |
Bayer AG vs. Competitors
-
Which has Higher Returns BAYZF or BNTX?
BioNTech SE has a net margin of -9.93% compared to Bayer AG's net margin of -1.89%. Bayer AG's return on equity of -0.91% beat BioNTech SE's return on equity of -3.01%.
Company Gross Margin Earnings Per Share Invested Capital BAYZFBayer AG55.41% -$1.15 $81.5B BNTXBioNTech SE90.24% -$0.14 $22B -
What do Analysts Say About BAYZF or BNTX?
Bayer AG has a consensus price target of --, signalling downside risk potential of --. On the other hand BioNTech SE has an analysts' consensus of $139.76 which suggests that it could grow by 26.57%. Given that BioNTech SE has higher upside potential than Bayer AG, analysts believe BioNTech SE is more attractive than Bayer AG.
Company Buy Ratings Hold Ratings Sell Ratings BAYZFBayer AG0 0 0 BNTXBioNTech SE14 5 0 -
Is BAYZF or BNTX More Risky?
Bayer AG has a beta of 0.626, which suggesting that the stock is 37.412% less volatile than S&P 500. In comparison BioNTech SE has a beta of 1.488, suggesting its more volatile than the S&P 500 by 48.755%.
-
Which is a Better Dividend Stock BAYZF or BNTX?
Bayer AG has a quarterly dividend of $0.13 per share corresponding to a yield of 0.23%. BioNTech SE offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bayer AG pays 4.24% of its earnings as a dividend. BioNTech SE pays out -- of its earnings as a dividend. Bayer AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios BAYZF or BNTX?
Bayer AG quarterly revenues are $11.3B, which are larger than BioNTech SE quarterly revenues of $1.8B. Bayer AG's net income of -$1.1B is lower than BioNTech SE's net income of -$33.5M. Notably, Bayer AG's price-to-earnings ratio is -- while BioNTech SE's PE ratio is 191.55x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bayer AG is 1.05x versus 7.51x for BioNTech SE. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BAYZFBayer AG1.05x -- $11.3B -$1.1B BNTXBioNTech SE7.51x 191.55x $1.8B -$33.5M
-
Which has Higher Returns BAYZF or IFRX?
InflaRx NV has a net margin of -9.93% compared to Bayer AG's net margin of -51538.49%. Bayer AG's return on equity of -0.91% beat InflaRx NV's return on equity of -82.01%.
Company Gross Margin Earnings Per Share Invested Capital BAYZFBayer AG55.41% -$1.15 $81.5B IFRXInflaRx NV-320.86% -$0.21 $54.4M -
What do Analysts Say About BAYZF or IFRX?
Bayer AG has a consensus price target of --, signalling downside risk potential of --. On the other hand InflaRx NV has an analysts' consensus of $10.46 which suggests that it could grow by 1098.21%. Given that InflaRx NV has higher upside potential than Bayer AG, analysts believe InflaRx NV is more attractive than Bayer AG.
Company Buy Ratings Hold Ratings Sell Ratings BAYZFBayer AG0 0 0 IFRXInflaRx NV5 2 0 -
Is BAYZF or IFRX More Risky?
Bayer AG has a beta of 0.626, which suggesting that the stock is 37.412% less volatile than S&P 500. In comparison InflaRx NV has a beta of 1.457, suggesting its more volatile than the S&P 500 by 45.659%.
-
Which is a Better Dividend Stock BAYZF or IFRX?
Bayer AG has a quarterly dividend of $0.13 per share corresponding to a yield of 0.23%. InflaRx NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bayer AG pays 4.24% of its earnings as a dividend. InflaRx NV pays out -- of its earnings as a dividend. Bayer AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios BAYZF or IFRX?
Bayer AG quarterly revenues are $11.3B, which are larger than InflaRx NV quarterly revenues of $27.8K. Bayer AG's net income of -$1.1B is lower than InflaRx NV's net income of -$14.3M. Notably, Bayer AG's price-to-earnings ratio is -- while InflaRx NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bayer AG is 1.05x versus 269.55x for InflaRx NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BAYZFBayer AG1.05x -- $11.3B -$1.1B IFRXInflaRx NV269.55x -- $27.8K -$14.3M
-
Which has Higher Returns BAYZF or IMTX?
Immatics NV has a net margin of -9.93% compared to Bayer AG's net margin of -974.45%. Bayer AG's return on equity of -0.91% beat Immatics NV's return on equity of -25.21%.
Company Gross Margin Earnings Per Share Invested Capital BAYZFBayer AG55.41% -$1.15 $81.5B IMTXImmatics NV-- -$0.49 $508.8M -
What do Analysts Say About BAYZF or IMTX?
Bayer AG has a consensus price target of --, signalling downside risk potential of --. On the other hand Immatics NV has an analysts' consensus of $19.13 which suggests that it could grow by 85.68%. Given that Immatics NV has higher upside potential than Bayer AG, analysts believe Immatics NV is more attractive than Bayer AG.
Company Buy Ratings Hold Ratings Sell Ratings BAYZFBayer AG0 0 0 IMTXImmatics NV9 0 0 -
Is BAYZF or IMTX More Risky?
Bayer AG has a beta of 0.626, which suggesting that the stock is 37.412% less volatile than S&P 500. In comparison Immatics NV has a beta of 1.359, suggesting its more volatile than the S&P 500 by 35.865%.
-
Which is a Better Dividend Stock BAYZF or IMTX?
Bayer AG has a quarterly dividend of $0.13 per share corresponding to a yield of 0.23%. Immatics NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bayer AG pays 4.24% of its earnings as a dividend. Immatics NV pays out -- of its earnings as a dividend. Bayer AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios BAYZF or IMTX?
Bayer AG quarterly revenues are $11.3B, which are larger than Immatics NV quarterly revenues of $6.1M. Bayer AG's net income of -$1.1B is lower than Immatics NV's net income of -$59.1M. Notably, Bayer AG's price-to-earnings ratio is -- while Immatics NV's PE ratio is 42.21x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bayer AG is 1.05x versus 13.76x for Immatics NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BAYZFBayer AG1.05x -- $11.3B -$1.1B IMTXImmatics NV13.76x 42.21x $6.1M -$59.1M
-
Which has Higher Returns BAYZF or MDGEF?
Medigene AG has a net margin of -9.93% compared to Bayer AG's net margin of --. Bayer AG's return on equity of -0.91% beat Medigene AG's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BAYZFBayer AG55.41% -$1.15 $81.5B MDGEFMedigene AG-- -- -- -
What do Analysts Say About BAYZF or MDGEF?
Bayer AG has a consensus price target of --, signalling downside risk potential of --. On the other hand Medigene AG has an analysts' consensus of -- which suggests that it could fall by --. Given that Bayer AG has higher upside potential than Medigene AG, analysts believe Bayer AG is more attractive than Medigene AG.
Company Buy Ratings Hold Ratings Sell Ratings BAYZFBayer AG0 0 0 MDGEFMedigene AG0 0 0 -
Is BAYZF or MDGEF More Risky?
Bayer AG has a beta of 0.626, which suggesting that the stock is 37.412% less volatile than S&P 500. In comparison Medigene AG has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock BAYZF or MDGEF?
Bayer AG has a quarterly dividend of $0.13 per share corresponding to a yield of 0.23%. Medigene AG offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bayer AG pays 4.24% of its earnings as a dividend. Medigene AG pays out -- of its earnings as a dividend. Bayer AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios BAYZF or MDGEF?
Bayer AG quarterly revenues are $11.3B, which are larger than Medigene AG quarterly revenues of --. Bayer AG's net income of -$1.1B is higher than Medigene AG's net income of --. Notably, Bayer AG's price-to-earnings ratio is -- while Medigene AG's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bayer AG is 1.05x versus -- for Medigene AG. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BAYZFBayer AG1.05x -- $11.3B -$1.1B MDGEFMedigene AG-- -- -- --
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Buy
56
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Sell
49
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 35x
Sell
44
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Sell
23
CAR alert for Feb 20
Avis Budget Group, Inc. [CAR] is down 0.3% over the past day.
Buy
75
HYMC alert for Feb 20
Hycroft Mining Holding Corp. [HYMC] is down 2.47% over the past day.
Sell
1
EPAM alert for Feb 20
EPAM Systems, Inc. [EPAM] is down 0.11% over the past day.
